MKC-1
Sponsors
Memorial Sloan Kettering Cancer Center, CASI Pharmaceuticals, Inc.
Conditions
Advanced CancerAgnogenic Myeloid MetaplasiaBreast CancerColorectal CancerEndometrial CancerHematological MalignanciesMyelodysplasiaNon-Small Cell Lung Cancer
Phase 1
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
CompletedNCT00014365
Start: 2000-10-31End: 2001-10-31Updated: 2013-06-18
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
CompletedNCT00003755
Start: 1998-10-31End: 2001-08-31Target: 40Updated: 2013-06-25
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
CompletedNCT00408226
Start: 2006-10-31End: 2012-01-31Updated: 2012-01-20
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
CompletedNCT00506402
Start: 2006-11-30End: 2009-04-30Target: 30Updated: 2009-05-05
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
CompletedNCT00656461
Start: 2008-03-31End: 2009-11-30Target: 24Updated: 2009-11-25
Phase 2
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
CompletedNCT00016250
Start: 2000-12-31End: 2002-06-30Updated: 2013-06-18
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
CompletedNCT00306631
Start: 2006-01-31End: 2008-11-30Updated: 2009-06-03
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
CompletedNCT00568646
Start: 2007-11-30End: 2009-05-31Target: 33Updated: 2011-08-04
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
CompletedNCT00607607
Start: 2008-01-31End: 2012-01-31Updated: 2012-01-20